Furthermore, VGF levels were lower in CSF of AD patients compared to controls and outperformed other biomarkers including CSF Aβ1-42, phosphorylated tau, and hippocampal volume in predicting MCI to AD conversion [32]. The gene discussed is MAPT; the disease is Alzheimer disease.